Larkindale added that this type of drug could, down the road, have application to many other diseases besides DMD that are now treated with glucocorticoids. Examples are myasthenia gravis (MG), dermatomyositis (DM), polymyositis (PM), asthma and rheumatoid arthritis.
ReveraGen has tested VB15 in mice with a DMD-like disease and has found it improved muscle function and reduced muscle inflammation.
"It is highly encouraging to see significant beneficial effects with VBP15 in mdx [DMD-like] mice," said Kanneboyina Nagaraju, co-founder of ReveraGen.
Edward Connor, interim CEO and president of ReveraGen, said, "VB15 is moving well through the drug development process. We are preparing for our initial regulatory interactions for DMD, and preclinical evaluation of other indications is ongoing."
To learn more, read the Quest News Online article MDA Funds Development of Gentler Glucocorticoid for DMD.
DMD is a degenerative muscle disease — affecting boys almost exclusively — that involves progressive degeneration of voluntary and cardiac muscles, with resulting weakness and heart abnormalities. The disease manifests in early childhood. Loss of the ability to walk occurs in most children with DMD between the ages of 10 and 12 years; weakened cardiac and respiratory muscles severely limit life span.
Glucocorticoid medications, such as prednisone and its chemical cousin prednisolone, slow disease progression and prolong walking ability.
About MDA Venture Philanthropy (MVP)
MVP is the Muscular Dystrophy Association's drug developme
|SOURCE Muscular Dystrophy Association|
Copyright©2010 PR Newswire.
All rights reserved